for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen reports Q4 beat on added boost from non-COVID-19 products

Feb 9 (Reuters) - U.S.-German genetic testing specialist Qiagen reported better-than-expected quarterly earnings on Tuesday, citing very strong demand for COVID-19 testing combined with improvements in non-COVID-19 areas of its portfolio.

Qiagen said fourth-quarter net sales rose 36% to $571.2 million on a currency-adjusted basis, beating the $539.14 million expected on average by analysts in a Vara Research poll, as improved trends for its QuantiFERON tuberculosis test, cancer diagnostics and DNA sample technologies complemented coronavirus-related sales.

The company confirmed its guidance for 2021 adjusted EPS and net sales growth. (Reporting by Zuzanna Szymanska in Gdansk Editing by Chris Reese)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up